The Samsung Life Science Fund has announced a strategic investment in Cartography Biosciences, a leading American biotech firm dedicated to developing advanced antibody-based oncology therapies. This significant partnership aims to accelerate the discovery and development of novel cancer treatments, leveraging the strengths of both organizations.
This strategic collaboration seeks to expedite the creation of new cancer therapies by combining Cartography Biosciences’ cutting-edge antigen discovery and drug development capabilities with Samsung’s extensive global expertise in life sciences investment and strategic growth. The alliance is poised to make substantial advancements in the oncology landscape.
Joseph Jeong, head of the Bio R&D Center at Samsung Biologics, emphasized the importance of this investment: “Cartography Biosciences exemplifies the next generation of biotechnology innovation, uniquely integrating large-scale data, advanced computational biology, and innovative therapeutic design to unlock novel cancer solutions. This investment underscores our unwavering commitment to supporting groundbreaking technologies that hold the potential to transform existing treatment paradigms and deliver profound impact to patients worldwide battling various cancers.”
Cartography Biosciences utilizes its proprietary Atlas and Summit platforms, which are engineered to integrate unique single-cell datasets with advanced computational biology and robust target validation capabilities. This sophisticated approach enables the precise identification of tumor-restricted antigens and critical antigen combinations, paving the way for highly targeted therapies. Currently, Cartography Biosciences’ flagship program, CBI-1214—a T-cell engager specifically designed for colorectal cancer—is actively enrolling patients in a crucial Phase 1 clinical trial.
Kevin Parker, CEO of Cartography Biosciences, expressed enthusiasm for the partnership, stating, “Samsung represents an ideal partner as we continue our vital mission of precisely mapping tumor biology to develop highly differentiated antibody-based therapies. We are incredibly excited to collaborate with such a distinguished global leader who clearly recognizes the immense value of new biotechnologies and cutting-edge biologic engineering in the discovery and advancement of novel biopharmaceuticals for cancer care.”
The Samsung Life Science Fund, a powerhouse established by Samsung Biologics, Samsung Bioepis, and Samsung C&T with a substantial total capital of 240 billion won (approximately $166 million), has consistently demonstrated its proactive investment strategy. The fund targets various firms specializing in next-generation biopharmaceutical technologies, encompassing diverse modalities such as biologics, gene editing, and innovative artificial intelligence-enabled therapeutics, driving forward the future of medicine.
hwkan
